- Report
- April 2025
- 90 Pages
Global
From €3500EUR$4,162USD£3,196GBP
- Report
- June 2025
- 131 Pages
Global
From €13507EUR$14,995USD£11,918GBP
- Report
- August 2025
- 98 Pages
Global
From €3500EUR$4,162USD£3,196GBP
- Report
- March 2025
- 1400 Pages
Global
From €4414EUR$4,900USD£3,895GBP
- Report
- June 2025
- 109 Pages
Global
From €3108EUR$3,450USD£2,742GBP
- Report
- June 2025
- 198 Pages
Global
From €4459EUR$4,950USD£3,934GBP
- Report
- February 2025
- 120 Pages
Global
From €3713EUR$4,123USD£3,277GBP
€4369EUR$4,850USD£3,855GBP
- Report
- August 2025
- 100 Pages
United States
From €3558EUR$3,950USD£3,140GBP
- Report
- August 2025
- 200 Pages
United States
From €2243EUR$2,490USD£1,979GBP
- Report
- March 2025
- 260 Pages
Middle East
From €2612EUR$2,900USD£2,305GBP
- Report
- March 2025
- 260 Pages
Africa
From €2612EUR$2,900USD£2,305GBP
- Report
- March 2025
- 210 Pages
Latin America
From €2612EUR$2,900USD£2,305GBP
- Report
- March 2025
- 840 Pages
Asia Pacific
From €2612EUR$2,900USD£2,305GBP
- Report
- March 2025
- 980 Pages
Europe
From €2612EUR$2,900USD£2,305GBP
- Report
- June 2025
- 81 Pages
Middle East, Africa
From €3108EUR$3,450USD£2,742GBP
- Report
- June 2025
- 97 Pages
Asia Pacific
From €3558EUR$3,950USD£3,140GBP
- Report
- June 2025
- 100 Pages
Europe
From €3558EUR$3,950USD£3,140GBP
- Report
- June 2025
- 89 Pages
North America
From €3108EUR$3,450USD£2,742GBP
- Report
- February 2025
- 236 Pages
United States
From €7202EUR$7,995USD£6,355GBP
- Report
- November 2023
- 127 Pages
Global
From €4054EUR$4,500USD£3,577GBP

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications.
The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more